Lundbeck: Vyepti promoted pre-authorisation at Migraine Trust virtual symposium (AUTH/3550/7/21)

📅 2021 | 🖉 Dr Anzal Qurbain
📊

Key facts

CaseAUTH/3550/7/21
PartiesHealth professional v Lundbeck
ProductVyepti (eptinezumab)
SettingMigraine Trust International Symposium (MTIS) virtual symposium (live) and on-demand hosting on MTIS website
Main issuePromotion of eptinezumab prior to UK marketing authorisation; ambiguous sponsorship declaration; on-demand content not properly restricted
Applicable Code year2019
Complaint received29 July 2021
Case completed26 July 2022
AppealNo appeal
Breach clauses2; 3.1; 9.1; 9.10
No breach clauses12.1 (and no breaches found in relation to the Vimeo video link)
SanctionsUndertaking received; Additional sanctions: Advertisement
Notes on scopeUK delegates were 18.2% (315) and the largest country group; invitation e-shots were sent to all delegates including UK HCPs

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • A health professional complained that Lundbeck promoted Vyepti (eptinezumab) before UK marketing authorisation via a session at the Migraine Trust International Symposium (MTIS) virtual event (Oct 2020).
  • The session included slides referencing eptinezumab’s mode of action, dosing, route of administration, EU approval status and clinical data (Promise-2).
  • Invitation “e-shots” to the Lundbeck symposium were sent to all registered delegates, including UK health professionals (UK was the largest delegate group at 18.2%).
  • The same symposium recording was later available as on-demand content on the MTIS website; part of the on-demand page was found not to require a registered user log-in (later updated).
  • The complainant also provided a Vimeo link; Lundbeck said this was a private technical Vimeo account used for hosting videos prior to embedding.
  • Sponsorship wording in the symposium included “Educational financial support provided by H. Lundbeck A/S”, which the Panel considered ambiguous about Lundbeck’s involvement and influence.
⚖️

Outcome

  • Breach found in relation to the live symposium and the on-demand video on the MTIS website.
  • No breach found in relation to the Vimeo link (complainant did not establish that the private Vimeo video was accessible as alleged).
  • No breach of Clause 12.1 (disguised promotion) on the narrow ground considered (initial impression at the outset).
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training